Request a Rep
Request a Rep

Redefining the Treatment Landscape for Symptomatic
NYHA Class II–III Obstructive HCM1,2

CAMZYOS® is the first and only approved cardiac myosin inhibitor that targets HCM at the source.1,2

CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin that helps to modulate the number of myosin heads in the off state.
This reduces the number of myosin-actin cross-bridges that form.1

Updated Phase 3 Clinical Trial Data
Clinical Trial Icon

Starting patients on CAMZYOS

Access to everything you need to start
appropriate patients on CAMZYOS.

Camzyos Finder Icon


Locate REMS-certified healthcare providers with CAMZYOS treatment experience

Getting Started Icon

CAMZYOS Resources

Find information about patient support, program details,
enrollment information, and downloadable resources.

HCM=hypertrophic cardiomyopathy; NYHA=New York Heart Association; REMS=Risk Evaluation and Mitigation Strategy.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.


  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2023.
  2. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.